Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

withdrawn117%
completed467%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

NCT02538614
completedphase_1

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

NCT02759016
completedphase_1

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

NCT01296932
completedphase_1

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

NCT01403948
completedphase_2

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

NCT02624492
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02538614Phase 1

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Terminated
NCT02759016Phase 1

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Completed
NCT01296932Phase 1

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Completed
NCT01403948Phase 1

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Completed
NCT02624492Phase 2

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Completed
NCT03343678Phase 1

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6